ESMO: Amgen's Imdelltra stages Rasonque-like moment in SCLC

Amgen's Imdelltra showed a 58% reduction in risk of death combined with AstraZeneca's Imfinzi in first-line maintenance treatment for extensive-stage small cell lung cancer, significantly improving overall survival by 8.4 months versus Imfinzi alone in a Phase 3 trial. This represents a major breakthrough for SCLC treatment and T-cell engager therapies in solid tumors.

This Wire brief sits within Fusion42's coverage of Biotech.